This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Goldman Sachs Remains a Hold on Baxter International (BAX)

Tipranks - Tipranks - Sat May 2, 6:36AM CDT

In a report released today, David Roman from Goldman Sachs maintained a Hold rating on Baxter International, with a price target of $19.00.

Claim 55% Off TipRanks

According to TipRanks, Roman is an analyst with an average return of -7.5% and a 38.54% success rate. Roman covers the Healthcare sector, focusing on stocks such as Boston Scientific, Baxter International, and Abbott Laboratories.

In addition to Goldman Sachs, Baxter International also received a Hold from TD Cowen’s Josh Jennings in a report issued yesterday. However, on April 24, Barclays reiterated a Buy rating on Baxter International (NYSE: BAX).

See today’s best-performing stocks on TipRanks >>

Based on Baxter International’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.97 billion and a GAAP net loss of $1.13 billion. In comparison, last year the company earned a revenue of $2.75 billion and had a GAAP net loss of $512 million

Read More on BAX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).